Clinical Trials Logo

Clinical Trial Summary

The Raydiant Oximetry Sensing System (Lumerah) is a non-invasive fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. Lumerah is intended as an adjunct to cardiotocography by detecting decreases in fetal oxygenation.


Clinical Trial Description

Raydiant Oximetry, Inc. is developing a novel and non-invasive fetal pulse oximetry device to fundamentally improve how fetuses are monitored during labor. The Raydiant Oximetry Sensing System (Lumerah) is a fetal pulse oximeter that measures fetal arterial oxygen saturation using safe, non-invasive, transabdominal near-infrared spectroscopy. Lumerah performs its measurements without the requirement for transvaginal placement and its associated risks. Lumerah is intended as an adjunct to cardiotocography by detecting fetal oxygen deprivation which is both life-threatening to the fetus and can lead to the irreversibly debilitating consequences of newborn metabolic acidosis. The severe consequences associated with newborn metabolic acidosis and the lack of availability of an effective tool to support its early diagnosis led to the development of Lumerah. In this study, women in labor will be simultaneously monitored with proven (previously FDA-approved) technology as a "ground truth". These women will be simultaneously monitored with both an external and internal oxygen sensor. Obstetric health-care providers are blinded to oximetry data presented by both devices; therefore, clinical decisions regarding interventions are made based on the standard factors, including cardiotocography. The primary efficacy analysis will be performed retrospectively by comparing data of fetal oxygenation displayed and recorded by both devices. Results of either the Lumerah external sensor or the internal sensor will not be used to guide or alter patient management. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05147584
Study type Interventional
Source Raydiant Oximetry, Inc.
Contact
Status Terminated
Phase N/A
Start date July 20, 2022
Completion date November 29, 2023

See also
  Status Clinical Trial Phase
Completed NCT02221440 - Maternal Oxygen Administration for Fetal Distress N/A
Completed NCT04325243 - Sildenafil Citrate and Intrapartum Fetal Distress Phase 4
Completed NCT03095937 - Evaluation of Fetal Cardiac Function in Rheumatic Heart Disease (RHD) Patients
Completed NCT00185887 - Nitroglycerin Versus Terbutaline for Intrapartum Fetal Resuscitation N/A
Completed NCT02862925 - Introducing Fetal Scalp Stimulation as an Adjunct to Intermittent Auscultation in Low-Resource Settings. N/A
Recruiting NCT06186973 - Fetal Assessment of the Myocardium and Evaluation of the Neonate
Recruiting NCT05681624 - Maternal Oxygen Supplementation for Intrauterine Resuscitation N/A
Completed NCT05946681 - Sildenafil Citrate to Improve Maternal and Neonatal Outcomes in Low-resource Settings
Completed NCT03536910 - Evaluation of Copeptin Levels in Elective Cesarean Section With Different Anesthetic Technique N/A
Completed NCT03156608 - Novii External Fetal Monitoring Device N/A
Recruiting NCT00246766 - Study of Fetal Movements Using Multichannel Ultrasound Pulsed Doppler in Normal and Pathologic Pregnancy N/A
Recruiting NCT04043299 - Effect of Intrapartum Oxygen Administration on Fetal and Early Neonatal Outcomes Phase 3
Not yet recruiting NCT03859037 - Effect of Umbilical Cord Milking on Transition of Preterm Babies During Resuscitation N/A
Completed NCT03370822 - A Mixed Methods Study to Explore the Feasibility of a Novel Continuous Fetal Monitoring Device
Not yet recruiting NCT05727241 - Three-dimensional Umbilical Cord Coiling Index
Terminated NCT04081584 - Trans-abdominal Fetal Pulse Oximetry: Tissue Light Scattering
Completed NCT03764696 - Maternal Oxygen Administration for Fetal Distress II N/A
Completed NCT01042262 - Maternal Oxygen Use During Delivery and Cord Blood Superoxide Dismutase N/A
Not yet recruiting NCT04548453 - Establish the uSI Values and End-user Training Material That Will be Used to Guide Oxytocin Dosing Actions Early Phase 1
Completed NCT03159234 - Prediction of Fetal Lung Maturity N/A